R. Lilenbaum

发表

Novel chemotherapeutic agents in the treatment of non-small-cell lung cancer.

M. Green, R. Lilenbaum, R. Lilenbaum, 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I study of paclitaxel and topotecan in patients with advanced tumors: a cancer and leukemia group B study.

G. Rosner, R. Schilsky, M. Ratain, 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II trial of weekly docetaxel in second‐line therapy for nonsmall cell lung carcinoma

R. Lilenbaum, E. Davila, M. Schwartz, 2001, Cancer.

Management of Patients with Advanced Non-Small-Cell Lung Cancer and Performance Status 2

R. Lilenbaum, 2006 .

Phase II study of PKC-α antisense oligonucleotide aprinocarsen in combination with gemcitabine and carboplatin in patients with advanced non-small cell lung cancer

C. Rudin, M. Edelman, W. John, 2006 .

Randomized phase III trial of single-agent pemetrexed versus carboplatin and pemetrexed in patients with advanced non-small-cell lung cancer and Eastern Cooperative Oncology Group performance status of 2.

C. Barrios, J. R. Pereira, C. Ferreira, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Expectations in the care of lung cancer.

N. Leighl, R. Lilenbaum, M. Neubauer, 2015, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

The Evolving Role of Cetuximab in Non–Small Cell Lung Cancer

R. Lilenbaum, 2006, Clinical Cancer Research.

Measuring the Impact of Academic Cancer Network Development on Clinical Integration, Quality of Care, and Patient Satisfaction.

A. Chiang, C. Fuchs, J. Kortmansky, 2018, Journal of oncology practice.

Summary Statement: Novel Agents in the Treatment of Lung Cancer: Advances in Epidermal Growth Factor Receptor-Targeted Agents

M. Meyerson, P. Jänne, Kwok-Kin Wong, 2006, Clinical Cancer Research.

A randomized phase III trial of single-agent pemetrexed (P) versus carboplatin and pemetrexed (CP) in patients with advanced non-small cell lung cancer (NSCLC) and performance status (PS) of 2.

C. Barrios, J. R. Pereira, C. Ferreira, 2012 .

Small Cell Lung Cancer: Past, Present, and Future

R. Lilenbaum, E. Rodriguez, 2010, Current oncology reports.

Safe pulmonary resection after chemotherapy and high-dose thoracic radiation.

M. Suntharalingam, L. Doyle, M. Krasna, 1999, The Annals of thoracic surgery.

Phase II Trial of Combined Modality Therapy with Myeloid Growth Factor Support in Patients with Locally Advanced Non-small Cell Lung Cancer

R. Lilenbaum, J. Pizzolato, M. Cusnir, 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Do older patients with non-small cell lung cancer also benefit from first-line platinum-based doublet chemotherapy? Observations from a pooled analysis of 730 prospectively-treated patients (Alliance Study A151622).

H. Cohen, M. Edelman, J. Feliciano, 2018, Journal of geriatric oncology.

Do Older Patients with Metastatic Non-Small Cell Lung Cancer Also Benefit from First-Line Platinum-Based Doublet Chemotherapy?: Observations from a Pooled Analysis of 730 Prospectively-Treated Patients (Alliance Study

H. Cohen, M. Edelman, J. Feliciano, 2018 .

Phase II randomized trial of vinorelbine and gemcitabine versus carboplatin and paclitaxel in advanced non-small-cell lung cancer.

P. Schwarzenberger, R. Lilenbaum, S. Lane, 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

Role of chemotherapy in patients with poor performance status and advanced non-small cell lung cancer.

C. Langer, R. Lilenbaum, 2004, Seminars in oncology.

Treatment of patients with advanced lung cancer and poor performance status.

R. Lilenbaum, 2004, Clinical lung cancer.

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer.

Robert Gray, R. Gray, J. Schiller, 2006, The New England journal of medicine.

New treatment strategies in patients with advanced non-small-cell lung cancer and performance status 2.

R. Lilenbaum, E. Rodriguez, 2008, Clinical lung cancer.

Single-agent versus combination chemotherapy in advanced non-small cell lung cancer (NSCLC): A CALGB randomized trial of efficacy, quality of life, and cost-effectiveness

C. Desch, J. Herndon, Mark R. Green, 2001 .

A phase II trial of cetuximab as therapy for recurrent non-small cell lung cancer (NSCLC).

N. Hanna, R. Govindan, T. Lynch, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Clinical responses to gefinitib after failure of treatment with cetuximab in advanced non-small-cell lung cancer.

L. Raez, G. Lopes, R. Lilenbaum, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Management of advanced non-small-cell lung cancer in elderly populations.

R. Lilenbaum, 2003, Clinical lung cancer.

Phase I study of paclitaxel and etoposide for metastatic or recurrent malignancies.

M. Green, R. Lilenbaum, D. MacManus, 1998, American journal of clinical oncology.

A Randomized Phase II Trial of Two Schedules of Docetaxel in Elderly or Poor Performance Status Patients with Advanced Non-small Cell Lung Cancer

J. Beaumont, A. Dowlati, R. Lilenbaum, 2007, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Severe 5-fluorouracil toxicity in a patient with decreased dihydropyrimidine dehydrogenase activity.

R. Diasio, R. Lilenbaum, B. E. Harris, 1993, Cancer investigation.

P3.02c-048 A Phase I/II Trial Evaluating the Combination of Stereotactic Body Radiotherapy and Pembrolizumab in Metastatic NSCLC: Topic: IT

R. Herbst, A. Chiang, D. Zelterman, 2017 .

Should health-related quality of life be measured in cancer symptom management clinical trials? Lessons learned using the functional assessment of cancer therapy.

J. Cashy, D. Cella, S. Yount, 2007, Journal of the National Cancer Institute. Monographs.

Multimodality therapy for non-small-cell lung cancer.

M. Green, R. Lilenbaum, 1994, Oncology.

The NCI Community Oncology Research Program: what every clinician needs to know.

W. McCaskill-Stevens, R. Lilenbaum, A. Lyss, 2013, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

Phase I study of topotecan and cisplatin in patients with advanced solid tumors: a cancer and leukemia group B study.

G. Rosner, R. Schilsky, R. Lilenbaum, 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

G. Rosner, R. Schilsky, M. Ratain, 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Options in advanced non-small cell lung cancer: a review and report on a phase II study of vinorelbine plus gemcitabine.

R. Lilenbaum, 2001, The oncologist.

Vinorelbine and gemcitabine combinations in advanced non small-cell lung cancer.

R. Herbst, R. Lilenbaum, 2000, Clinical lung cancer.

Gemcitabine and vinorelbine in advanced nonsmall cell lung carcinoma

R. Lilenbaum, J. Lutzky, E. Davila, 2000, Cancer.

Extranodal lymphoplasmacytoid lymphoma (immunocytoma) presenting as small intestinal obstruction.

R. Lilenbaum, M. Recine, M. Robinson, 2009, Archives of pathology & laboratory medicine.

Stereotactic body radiotherapy in patients with stage I non-small-cell lung cancer aged 75 years and older: retrospective results from a multicenter consortium.

S. Kandula, A. Gajra, J. Bogart, 2013, Clinical lung cancer.

Phase II trial of weekly docetaxel (D) in second-line non-small cell lung cancer (NSCLC)

R. Lilenbaum, E. Davila, L. Siegel, 2000 .

Randomized phase II trial of docetaxel plus cetuximab or docetaxel plus bortezomib in patients with advanced non-small-cell lung cancer and a performance status of 2: CALGB 30402.

E. Vokes, R. Lilenbaum, L. Gu, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I and pharmacologic study of continuous infusion topotecan in combination with cisplatin in patients with advanced cancer: a Cancer and LeukemiaGroup B study.

G. Rosner, R. Schilsky, M. Ratain, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II randomized trial of irinotecan/docetaxel (ID) or irinotecan/gemcitabine (IG) with or without celecoxib (CBX) in 2nd-line treatment of non-small-cell lung cancer (NSCLC).

M. Socinski, L. Hart, R. Lilenbaum, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I study of irinotecan (Ir) and cisplatin (DDP) in combination with thoracic radiotherapy (RT), either twice daily (45 Gy) or once daily (70 Gy), in patients with limited (Ltd) small cell lung carcinoma (SCLC): Early analysis of RTOG 0241.

W. Curran, H. Choy, S. Swann, 2006, Journal of Clinical Oncology.

New developments in chemotherapy for advanced non-small cell lung cancer

L. Raez, R. Lilenbaum, 2006, Current opinion in oncology.

The spectrum of neuroendocrine tumors: histologic classification, unique features and areas of overlap.

H. Beltran, D. Klimstra, R. Lilenbaum, 2015, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

Gefitinib versus placebo in completely resected non-small-cell lung cancer: results of the NCIC CTG BR19 study.

J. Jett, F. Khuri, H. Choy, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Single-agent versus combination chemotherapy in advanced non-small cell lung cancer: a meta-analysis and the Cancer and Leukemia Group B randomized trial.

C. Desch, R. Lilenbaum, M. List, 1999, Seminars in oncology.

American Society of Clinical Oncology perspective: Raising the bar for clinical trials by defining clinically meaningful outcomes.

L. Ellis, C. Sima, D. Sargent, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Single agent versus combination chemotherapy in patients with advanced nonsmall cell lung carcinoma

K. Dickersin, P. Langenberg, R. Lilenbaum, 1998, Cancer.

Chemotherapeutic management of stage IV non-small cell lung cancer.

David E Morris, M. Socinski, R. Lilenbaum, 2003, Chest.

Management of advanced non-small-cell lung cancer in patients with a performance status of 2.

R. Lilenbaum, 2004, Clinical lung cancer.

Randomized phase 2 study of tivantinib plus erlotinib versus single-agent chemotherapy in previously treated KRAS mutant advanced non-small cell lung cancer.

Chao Huang, M. Socinski, J. Neal, 2018, Lung cancer.

Treatment of Elderly Patients With Non-Small-Cell Lung Cancer: Results of an International Expert Panel Meeting of the Italian Association of Thoracic Oncology.

C. Gridelli, E. Felip, F. de Marinis, 2015, Clinical lung cancer.

Advances in the Treatment of Metastatic Non–Small-Cell Lung Cancer With Chemotherapy and Targeted Agents

R. Herbst, R. Lilenbaum, 2008 .

Treatment of non-small cell lung cancer, stage IV: ACCP evidence-based clinical practice guidelines (2nd edition).

M. Socinski, R. Crowell, C. Langer, 2007, Chest.

Practice Guidelines ( 2 nd Edition ) Stage IV : ACCP Evidence-Based Clinical Treatment of Non-small Cell Lung Cancer

M. Socinski, R. Crowell, C. Langer, 2007 .

Randomized phase III trial comparing cisplatin-etoposide to carboplatin-paclitaxel in advanced or metastatic non-small cell lung cancer.

M. Socinski, K. Rowland, R. Lilenbaum, 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

Combining EGF receptor inhibitors with chemotherapy or chemoradiotherapy in patients with non-small-cell lung cancer

R. Lilenbaum, B. Bastos, 2011 .

A phase II trial of cetuximab as therapy for recurrent non-small cell lung cancer (NSCLC): Final results

P. Jänne, N. Hanna, R. Govindan, 2005 .

Single-agent versus combination chemotherapy in advanced non-small-cell lung cancer: the cancer and leukemia group B (study 9730).

J. Holland, C. Desch, J. Herndon, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Molecular Analysis-Based Treatment Strategies for the Management of Non-small Cell Lung Cancer

L. Sequist, A. Wozniak, D. Harpole, 2009, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Phase II trial of cetuximab in patients with previously treated non-small-cell lung cancer.

P. Jänne, N. Hanna, R. Govindan, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Single-Agent Versus Combination Chemotherapy in Patients with Advanced Non-small Cell Lung Cancer and a Performance Status of 2: Prognostic Factors and Treatment Selection Based on Two Large Randomized Clinical Trials

M. Socinski, K. O'Byrne, J. Singer, 2009, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Role of Chemoradiotherapy in Elderly Patients With Limited-Stage Small-Cell Lung Cancer

L. Wilson, R. Decker, James B. Yu, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

New Horizons in Chemotherapy: Platforms for Combinations in First-Line Advanced Non-small Cell Lung Cancer

R. Lilenbaum, 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Randomized phase II trial of docetaxel/irinotecan and gemcitabine/irinotecan with or without celecoxib in the second-line treatment of non-small-cell lung cancer.

M. Socinski, N. Altorki, L. Hart, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Efficacy and Safety of Oxaliplatin and Gemcitabine with Bevacizumab in Advanced Non-small Cell Lung Cancer

L. Raez, J. Tseng, R. Lilenbaum, 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Randomized phase II trial of erlotinib or standard chemotherapy in patients with advanced non-small-cell lung cancer and a performance status of 2.

A. Dowlati, R. Lilenbaum, R. Axelrod, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Patients with non-small cell lung cancer and poor performance status: a significant population with limited data.

C. Langer, R. Lilenbaum, 2004, Seminars in oncology.

Optimizing Treatment Risk and Benefit for Elderly Patients With Advanced Non-Small-Cell Lung Cancer: The Right Treatment for the Right Patient.

C. Gross, C. Presley, R. Lilenbaum, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The Treatment of Advanced Lung Cancer in the Elderly: The Role of a Comprehensive Geriatric Assessment and Doublet Chemotherapy

C. Presley, R. Lilenbaum, 2015, Cancer journal.

Primary hepatic neuroendocrine carcinoma: an underdiagnosed entity.

R. Lilenbaum, J. Shoosmith, Raymund Dala, 2006, Annals of diagnostic pathology.

Case Reports Primary hepatic neuroendocrine carcinoma: an underdiagnosed entity

R. Lilenbaum, J. Shoosmith, Raymund Dala, 2006 .

A Phase II Study of Induction Chemotherapy Followed by Thoracic Radiotherapy and Erlotinib in Poor-Risk Stage III Non–Small-Cell Lung Cancer: Results of CALGB 30605 (Alliance)/RTOG 0972 (NRG)

P. Jänne, J. Bradley, E. Vokes, 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Generalizability of trial results to elderly Medicare patients with advanced solid tumors (Alliance 70802).

H. Cohen, E. Lamont, R. Schilsky, 2015, Journal of the National Cancer Institute.

Development of Imminent Mortality Predictor for Advanced Cancer (IMPAC), a Tool to Predict Short-Term Mortality in Hospitalized Patients With Advanced Cancer.

Junchao Ma, Donald K. K. Lee, Edieal J. Pinker, 2017, Journal of oncology practice.

Time‐to‐Treatment‐Failure and Related Outcomes Among 1000+ Advanced Non–Small Cell Lung Cancer Patients: Comparisons Between Older Versus Younger Patients (Alliance A151711)

H. Cohen, M. Edelman, J. Feliciano, 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Issues at the cutting edge in stage III non-small-cell lung cancer.

M. Green, R. Lilenbaum, 1995, Annals of oncology : official journal of the European Society for Medical Oncology.

A phase II randomized trial of docetaxel weekly or every 3 weeks in elderly and/or poor performance status (PS) patients (pts) with advanced non-small cell lung cancer (NSCLC).

R. Lilenbaum, T. Chidiac, L. Seigel, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Chemotherapy for elderly patients with advanced non-small-cell lung cancer.

P. Bunn, R. Lilenbaum, 2003, Journal of the National Cancer Institute.

Combined modality therapy for limited-disease small cell lung cancer

L. Raez, R. Lilenbaum, M. Samuels, 2005, Current treatment options in oncology.

Unusual presentation and location pleural malignant mesothelioma

R. Lilenbaum, A. Hadeh, C. Carcano, 2013, BMJ Case Reports.

Criterion validity of Medicare chemotherapy claims in Cancer and Leukemia Group B breast and lung cancer trial participants.

John D. Roberts, C. Bloomfield, N. Christakis, 2005, Journal of the National Cancer Institute.

Chemotherapy in Patients ≥80 with Advanced Non-small Cell Lung Cancer: Combined Results from SWOG 0027 and LUN 6

J. Crowley, D. Gandara, K. Chansky, 2007, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Stage IIIA category of non-small-cell lung cancer: a new proposal.

M. Green, R. Lilenbaum, 1994, Journal of the National Cancer Institute.

Emergency department (ED) utilization and hospital admission rates among oncology patients at a large academic center and the need for improved urgent care access.

R. Lilenbaum, V. Dest, R. Lisitano, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Preparing for Value-Based Payment: A Stepwise Approach for Cancer Centers.

B. Chaudhry, Kavita K. Patel, R. Lilenbaum, 2016, Journal of oncology practice.

A phase I trial of paclitaxel and etoposide for metastatic or recurrent malignancies.

M. Green, R. Lilenbaum, D. MacManus, 1995, Seminars in oncology.

Phase II trial of oxaliplatin and gemcitabine with bevacizumab in first-line advanced non-small cell lung cancer (NSCLC).

L. Raez, J. Tseng, R. Lilenbaum, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prevalence of Poor Performance Status in Lung Cancer Patients: Implications for Research

J. Cashy, D. Cella, T. Hensing, 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Topotecan therapy in patients with relapsed small-cell lung cancer and poor performance status.

R. Huber, R. Lilenbaum, G. Masters, 2006, Clinical lung cancer.

Measuring Clinically Significant Chemotherapy-Related Toxicities Using Medicare Claims From Cancer and Leukemia Group B (CALGB) Trial Participants

N. Christakis, E. Lamont, R. Schilsky, 2008, Medical care.

Accrual to National Cancer Institute-sponsored non-small-cell lung cancer trials: insights and contributions from the CCOP program.

R. Lilenbaum, A. Lyss, Alan P Lyss, 2009, Clinical lung cancer.

Insulin growth factor pathway.

R. Lilenbaum, 2009, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Treatment of taste alterations in chemotherapy patients using the "miracle fruit": Preliminary analysis of a pilot study.

J. Beaumont, D. Eton, H. Soares, 2010 .

Differences in clinical trial patient attributes and outcomes according to enrollment setting.

B. McNeil, E. Lamont, N. Keating, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Systemic treatment of Kaposi's sarcoma: current status and future directions.

R. Lilenbaum, L. Ratner, 1994, AIDS.

The efficacy and cost effectiveness of new antiemetic guidelines.

R. Lilenbaum, C. Engstrom, I. Hernandez, 1999, Oncology nursing forum.

American Society of Clinical Oncology perspective: Raising the bar for clinical trials by defining clinically meaningful outcomes.

L. Ellis, C. Sima, D. Sargent, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A Phase II Study of Induction Chemotherapy Followed by Thoracic Radiotherapy and Erlotinib in Poor-Risk Stage III Non–Small-Cell Lung Cancer: Results of CALGB 30605 (Alliance)/RTOG 0972 (NRG)

P. Jänne, J. Bradley, E. Vokes, 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Treatment of advanced non-small-cell lung cancer in special populations.

R. Lilenbaum, 2004, Oncology.

Chemotherapy in patients ≥ 80 with advanced non-small cell lung cancer: combined results from SWOG 0027 and LUN 6

D. Gandara, K. Chansky, A. Dowlati, 2005 .

Randomized phase II trial of single agent erlotinib vs. standard chemotherapy in patients with advanced non-small cell lung cancer (NSCLC) and performance status (PS) of 2.

A. Dowlati, R. Lilenbaum, D. Bodkin, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.